355 related articles for article (PubMed ID: 2425567)
21. Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc.
Marone G; Findlay SR; Lichtenstein LM
J Pharmacol Exp Ther; 1981 May; 217(2):292-8. PubMed ID: 6164779
[TBL] [Abstract][Full Text] [Related]
22. The mechanism of mediator release from human basophils induced by platelet-activating factor.
Columbo M; Casolaro V; Warner JA; MacGlashan DW; Kagey-Sobotka A; Lichtenstein LM
J Immunol; 1990 Dec; 145(11):3855-61. PubMed ID: 1700998
[TBL] [Abstract][Full Text] [Related]
23. Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells.
Patella V; Casolaro V; Björck L; Marone G
J Immunol; 1990 Nov; 145(9):3054-61. PubMed ID: 1698870
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs.
Marone G; Stellato C; Mastronardi P; Mazzarella B
Ann Fr Anesth Reanim; 1993; 12(2):116-25. PubMed ID: 7690200
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release.
Schulman ES; Post TJ; Henson PM; Giclas PC
J Clin Invest; 1988 Mar; 81(3):918-23. PubMed ID: 2449462
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.
Cirillo R; Triggiani M; Siri L; Ciccarelli A; Pettit GR; Condorelli M; Marone G
J Immunol; 1990 May; 144(10):3891-7. PubMed ID: 1692065
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the anti-inflammatory effect of FK-506 on human mast cells.
de Paulis A; Cirillo R; Ciccarelli A; de Crescenzo G; Oriente A; Marone G
J Immunol; 1991 Dec; 147(12):4278-85. PubMed ID: 1721644
[TBL] [Abstract][Full Text] [Related]
28. General anaesthetics induce only histamine release selectively from human mast cells.
Stellato C; Casolaro V; Ciccarelli A; Mastronardi P; Mazzarella B; Marone G
Br J Anaesth; 1991 Dec; 67(6):751-8. PubMed ID: 1722691
[TBL] [Abstract][Full Text] [Related]
29. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release.
Stellato C; Cirillo R; de Paulis A; Casolaro V; Patella V; Mastronardi P; Mazzarella B; Marone G
Anesthesiology; 1992 Nov; 77(5):932-40. PubMed ID: 1280014
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol.
Marone G; Ambrosio G; Bonaduce D; Genovese A; Triggiani M; Condorelli M
Int Arch Allergy Appl Immunol; 1984; 74(4):356-61. PubMed ID: 6203844
[TBL] [Abstract][Full Text] [Related]
31. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells.
Patella V; de Crescenzo G; Marino O; Spadaro G; Genovese A; Marone G
Int Arch Allergy Immunol; 1996 Sep; 111(1):23-9. PubMed ID: 8753840
[TBL] [Abstract][Full Text] [Related]
32. Modulation of rat peritoneal mast cell and human basophil histamine release by estrogens.
Cocchiara R; Albeggiani G; Di Trapani G; Azzolina A; Lampiasi N; Rizzo F; Geraci D
Int Arch Allergy Appl Immunol; 1990; 93(2-3):192-7. PubMed ID: 1712002
[TBL] [Abstract][Full Text] [Related]
33. The effect of tyrosine kinase inhibitors on IgE-mediated histamine release from human lung mast cells and basophils.
Lavens-Phillips SE; Mockford EH; Warner JA
Inflamm Res; 1998 Mar; 47(3):137-43. PubMed ID: 9562339
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of human mast cells and basophils. Effects of a putative 5-lipoxygenase inhibitor.
Cohan V; McKenzie-White J; Triggiani M; Massey W; Kagey-Sobotka A; Lichtenstein LM
Biochem Pharmacol; 1989 Dec; 38(24):4455-9. PubMed ID: 2481451
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of the effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet activating factor on histamine and leukotriene C4 release from human leukocytes.
Columbo M; Horowitz EM; Patella V; Kagey-Sobotka A; Chilton FH; Lichtenstein LM
J Allergy Clin Immunol; 1993 Aug; 92(2):325-33. PubMed ID: 7688778
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human basophil leukotriene release by antiinflammatory steroids.
Schleimer RP; Davidson DA; Peters SP; Lichtenstein LM
Int Arch Allergy Appl Immunol; 1985; 77(1-2):241-3. PubMed ID: 3874167
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
38. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli.
Warner JA; Peters SP; Lichtenstein LM; Hubbard W; Yancey KB; Stevenson HC; Miller PJ; MacGlashan DW
J Leukoc Biol; 1989 Jun; 45(6):558-71. PubMed ID: 2470847
[TBL] [Abstract][Full Text] [Related]
39. The effect of recombinant stem cell factor on human skin and lung mast cells and basophil leukocytes.
Frenz AM; Gibbs BF; Pearce FL
Inflamm Res; 1997 Feb; 46(2):35-9. PubMed ID: 9085141
[TBL] [Abstract][Full Text] [Related]
40. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release.
Stellato C; de Crescenzo G; Patella V; Mastronardi P; Mazzarella B; Marone G
J Allergy Clin Immunol; 1996 Mar; 97(3):838-50. PubMed ID: 8613641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
